Fruquintinib With PD-1 Inhibitors Versus TAS-102 With Bevacizumab in Late-Line mCRC

Condition:   Metastatic Colorectal Adenocarcinoma Interventions:   Drug: Fruquintinib;   Drug: PD-1 inhibitors;   Drug: Trifluridine/Tipiracil;   Drug: Bevacizumab Sponsor:   Hunan Cancer Hospital Completed
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials